Clinical practice utilizes the status of estrogen receptor (ER), progesterone receptor (PR), and HER2 hormone receptors to categorize breast cancer, enabling the optimization of personalized therapeutic strategies for each patient [9,10]. Here, ERBB2 is linked to breast carcinoma.